# Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

> **NCT01889797** · PHASE2 · TERMINATED · sponsor: **PrECOG, LLC.** · enrollment: 32 (actual)

## Conditions studied

- Indolent Non-Hodgkin's Lymphoma

## Interventions

- **BIOLOGICAL:** Arm A: Rituximab
- **BIOLOGICAL:** Arm B: GA101

## Key facts

- **NCT ID:** NCT01889797
- **Lead sponsor:** PrECOG, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-12
- **Primary completion:** 2016-04
- **Final completion:** 2016-08
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Closed due prolonged enrollment timelines
- **Last updated:** 2017-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01889797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01889797, "Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01889797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*